Search

Search Results

• 

  A short history of anti-rheumatic therapy - VII. Biological agents

  G. Pasero, P. Marson, B. Gatto

  185-194

  09-11-2011

  https://doi.org/10.4081/reumatismo.2011.185

  1810

  PDF: 1342

• Central nervous system involvement in patients with HCV-related cryoglobulinemia: review and a case report

  D. Filippini, F. Colombo, S. Jann, R. Corneo, B. Canesi

  150-155

  https://doi.org/10.4081/reumatismo.2002.150

  1640

  PDF: 1882
• 

  Are biological drugs safe in pregnancy?

  A. Calligaro, A. Hoxha, A. Ruffatti, L. Punzi

  304-317

  31-03-2015

  https://doi.org/10.4081/reumatismo.2014.798

  4217

  PDF: 2649

• PO:10:149 | Efficacy of anifrolumab in a case of systemic lupus erythematosus with pulmonary involvement Fabio Brandolino¹, Giulia Pazzola¹, Luca Ronzoni³, Andreina Teresa Manfredi^1|2, Carlo Salvarani^1|2 | ¹SC Reumatologia, IRCCS Arcispedale Santa Maria Nuova, AUSL Reggio Emilia; ²Università di Modena e Reggio Emilia, Scuola di specializzazione in Reumatologia, Modena; ³SC Malattie dell'Apparato Respiratorio, IRCCS Arcispedale Santa Maria Nuova, AUSL Reggio Emilia, Italy

  Società Italiana di Reumatologia

  25-11-2025

  https://doi.org/10.4081/reumatismo.2025.2146

  247

• Leishmaniasis in rheumatoid arthritis

  C. Pizzorni, M.E. Secchi, M. Cutolo

  235-239

  https://doi.org/10.4081/reumatismo.2007.235

  1720

  PDF: 1112

• PO:18:276 | Use of anifrolumab in the treatment of difficult-to-treat manifestations in systemic lupus erythematosus Antonella Grimaldi¹, Giuseppe Alessandrini², Laura Quarta¹, Maria Rita Ricciardi¹, Daniela Costanza¹, Clara Minerba¹, Eugenio Quarta¹ | ¹UOC Reumatologia Verona; ²Specialista Dermatologo in Libera Professione, Italy

  Società Italiana di Reumatologia

  25-11-2025

  https://doi.org/10.4081/reumatismo.2025.2170

  216

• PO:11:171 | Subcutaneous tocilizumab use in a young-onset mixed connective tissue disease patient with multiple treatment failures Rhaysa Araujo Mousinho¹, Elide Lupi², Massimiliano Limonta² | ¹Clinica di Reumatologia, Dipartimento di Medicina and ²Istituto di Anatomia Patologica, Dipartimento di Medicina di Laboratorio, Osp. S. M. della Misericordia, Università di Udine, Italy

  Società Italiana di Reumatologia

  25-11-2025

  https://doi.org/10.4081/reumatismo.2025.2154

  198

• Differences in pharmacology of tumor necrosis factor (TNF) antagonists

  U. Fiocco, S. Bombardieri

  8-16

  https://doi.org/10.4081/reumatismo.2005.4s.8

  1382

  PDF: 1848

• PO:35:223 | Biologic therapy for sustained remission in eosinophilic myocarditis: real-world evidence from a tertiary center experience Federica Davanzo¹, Caterina Menghi², Andrea Silvio Giordani², Anna Baritussio², Federico Scognamiglio², Cristina Vicenzetto², Luca Iorio¹, Renzo Marcolongo², Cristina Basso³, Andrea Doria¹, Roberto Padoan¹, Alida Linda Patr Caforio² | ¹Rheumatology Unit, Department of Medicine, University of Padua Padova, Italy; ²Cardiology Unit, Department of Cardiac, Vascular, Thoracic Sciences and Public Health, University of Padua Padova, Italy; ³Cardiovascular Pathology, Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua Padova, Italy

  Società Italiana di Reumatologia

  18-03-2026

  https://doi.org/10.4081/reumatismo.2025.2383

  52

• Treatment of Wegener’s granulomatosis

  V. Riccieri, G. Valesini

  69-76

  https://doi.org/10.4081/reumatismo.2004.69

  1502

  PDF: 5329

• PO:37:260 | Mepolizumab in the treatment of patients with eosinophilic granulomatosis with polyangiitis: real-life experience from a single-center cohort Eleonora Bruschi¹, Fabrizio Angeli¹, Alessandro Belotti Masserini¹, Stefania Bertocchi¹, Silvia Breda¹, Elide Lupi¹, Valeria Rossi¹, Tania Ubiali¹, Massimiliano Limonta¹ | ¹ASST Papa Giovanni XXIII Bergamo Italy

  Società Italiana di Reumatologia

  25-11-2025

  https://doi.org/10.4081/reumatismo.2025.2220

  177